ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2013
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility.bioRxiv : the preprint server for biology · 2026Article
- Unveiling genomic rearrangements in engineered iPSC lines by optical genome mapping.Molecular therapy. Methods & clinical development · 2025Article
- Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.Experimental hematology & oncology · 2024Review
- Challenges and new technologies in adoptive cell therapy.Journal of hematology & oncology · 2023Review
- Article
- Article
- Autologous antigen-presenting cells efficiently expandMolecular therapy. Methods & clinical development · 2021Article
- Article
- Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.Advanced healthcare materials · 2020Article
- PiggyBac-modified CD19-expressing 4T1 cell line for the evaluation of CAR construct.International journal of clinical and experimental pathology · 2019Article
- Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo.Nature communications · 2018Article
- Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor inMolecular therapy. Methods & clinical development · 2018Article
- Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.Cell death & disease · 2018Article
- Histone deacetylation, as opposed to promoter methylation, results in epigeneticOncology letters · 2018Article
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Nature nanotechnology · 2017Article
- The Functionality of Minimal PiggyBac Transposons in Mammalian Cells.Molecular therapy. Nucleic acids · 2016Article
- Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells.Nucleic acids research · 2015Article
- Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.PloS one · 2015Article
- Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.Cytotherapy · 2014Article
- An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
The piggyBac transposon system is a promising nonviral method to genetically modify T cells for immunotherapeutic applications. To evaluate the regulation and stability of transgene expression in human T cells modified with piggyBac-transposons, peripheral blood mononuclear cells were nucleofected with transposase and an enhanced green fluorescence protein (eGFP)-expressing transposon. Single-cell clones that were subsequently stimulated and expanded exhibited homogenous eGFP expression for >26 weeks in culture. CD3 stimulation of the T-cell receptor together with CD28-mediated costimulation resulted in an approximate 10-fold transient increase in eGFP expression, but immunomodulatory cytokines, including interferon-γ, interleukin-12, interleukin-4, and transforming growth factor-β, did not alter transgene expression in actively dividing, activated, or resting T cells. Epigenetic modification with 5-azacytidine or trichostatin-A increased transgene expression indicating that piggyBac-mediated transgene expression could be modulated by methylation or histone acetylation, respectively. We performed transposon copy number analysis of populations of stably transfected T cells, comparing transposon plasmids of 5.6 and 3.5 kb. The smaller vector achieved an average of 22 transposon copies per cell, whereas the larger vector achieved 1.6 copies/cell, implying that transposon copy number can be engineered to be low or high depending on the vector used. Our results provide important insight into the ability of piggyBac to achieve stable genetic modification of T cells for immunotherapy applications and how transgene expression might be regulated by TCR activation, cytokines, and epigenetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.